Time for Change in NASH: How Non-Invasive Biomarkers Are Driving a Paradigm Shift in Clinical Trials and Clinical Care

Currently, many different imaging and blood-based NITs are being explored in clinical trials. In some trials, pre-biopsy enrichment strategies with NITs are becoming increasingly popular to reduce the number of liver biopsy-related screen failures. While the identification of patients at high risk of progressive NASH remains an on-going challenge, there is a wealth of emerging data from clinical trials that will directly influence future NIT use in NASH clinical care. Listen to our webinar to learn how non-invasive biomarkers are driving a paradigm shift in NASH clinical trials and clinical care.